<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26312693</article-id>
      <article-id pub-id-type="pmc">4540527</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20153834</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Drug-induced lupus with leukocytoclastic vasculitis: a rare expression
associated with adalimumab<xref ref-type="fn" rid="fn01">*</xref></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Amarante</surname>
            <given-names>Carolina Forte</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Acedo</surname>
            <given-names>Livia Mendes Sabia</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rabay</surname>
            <given-names>F&#xE1;tima Maria de Oliveira</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Campos</surname>
            <given-names>Benedito do Esp&#xED;rito Santo</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lira</surname>
            <given-names>M&#xE1;rcia Lanzoni de Alvarenga</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mandelbaum</surname>
            <given-names>Samuel Henrique</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <aff id="aff01"><label>1</label>University of Taubat&#xE9; (UNITAU) - Taubat&#xE9; (SP),
Brazil.</aff>
      </contrib-group>
      <author-notes>
        <corresp id="c01">MAILING ADDRESS: Carolina Forte Amarante, Avenida Granadeiro
Guimar&#xE3;es, 270, Centro, 12.020-130 - Taubat&#xE9; - SP, Brazil. E-mail:
<email>carol_amarante88@hotmail.com</email></corresp>
        <fn fn-type="conflict">
          <p>Conflict of Interest: None.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <volume>90</volume>
      <issue>3 Suppl 1</issue>
      <fpage>121</fpage>
      <lpage>124</lpage>
      <history>
        <date date-type="received">
          <day>12</day>
          <month>7</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>04</day>
          <month>8</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2015 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>TNF alpha antagonist-induced lupus-like syndrome is a rare condition which
predominantly affects women (4:1). The average age of onset is 46-51 years. It occurs
after exposure to TNF alpha antagonist and disappears after discontinuation of such
agents. The pathogenic mechanism for development of the TNF alpha antagonist-induced
lupus-like syndrome is not fully defined. It is believed that the medication induces
apoptosis, leading to an accumulation of nucleosomal antigens of apoptotic cells.
This would cause autoantibodies to be produced by susceptible individuals. The most
common cutaneous manifestations include maculopapular exanthem, malar rash, alopecia,
photosensitivity and, more rarely, vasculitis. Extracutaneous manifestations include:
fever, weight loss, arthritis or arthralgia, myositis and hematological
abnormalities. Antinuclear antibody may be positive in 80% of cases and anti-histone
antibody is considered a disease marker for TNF alpha antagonist-induced lupus-like
syndrome. Treatment corresponds to drug discontinuation. We report a rare case of
sub-acute cutaneous lupus erythematosus with leukocytoclastic vasculitis induced by
adalimumab in a 42-year-old patient.</p>
      </abstract>
      <kwd-group>
        <kwd>Exposure to biological agents</kwd>
        <kwd>Tumor necrosis factor-alpha</kwd>
        <kwd>Vasculitis, leukocytoclastic, cutaneous</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Tumor necrosis factor (TNF) alpha is a pro-inflammatory cytokine that is implicated in
the pathogenesis of many chronic inflammatory diseases, including rheumatoid arthritis,
ankylosing spondylitis, inflammatory bowel disease and psoriatic arthritis.<sup><xref rid="r01" ref-type="bibr">1</xref>-<xref rid="r09" ref-type="bibr">9</xref></sup>
TNF alpha antagonists were developed over a decade ago and have shown increasing success
in controlling these diseases.<sup><xref rid="r06" ref-type="bibr">6</xref></sup> One of
the most common side-effects is the development of autoantibodies. Although the
development of different autoantibodies is a common finding, only a few cases of
drug-induced lupus erythematosus have been reported and they are rarely related to
adalimumab.<sup><xref rid="r01" ref-type="bibr">1</xref>-<xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r07" ref-type="bibr">7</xref>,<xref rid="r08" ref-type="bibr">8</xref></sup> We report a rare case of Sub-acute cutaneous lupus
erythematosus with leukocytoclastic vasculitis induced by adalimumab in a 42-year-old
patient.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A 42-year-old male patient had a 10-year-history of psoriasis vulgaris and scalp
psoriasis. After complaining of pain in the sacroiliac joint and knee, axial psoriatic
arthritis was diagnosed. The laboratory tests showed elevated inflammatory markers, with
negative antinuclear antibodies and rheumatoid factor. Methotrexate (15mg
subcutaneously) plus narrowband UVB was introduced. However, given the decline in
therapeutic efficacy, we decided to change to immunobiological therapy with adalimumab.
The patient received adalimumab 40 mg subcutaneously every two weeks plus topical
calcipotriol, and showed good response to therapy. After 22 months of treatment, the
patient complained of myalgia, arthralgia in the wrists and elbows, fever of 38 degrees
and appearance of skin lesions. Dermatological examination revealed discrete purpuric
papules on the ends of the fingers and periungual telangiectasias. There were no other
systemic signs. Laboratory evaluation showed elevated ESR, positive ANA at a titer of 1:
640 with homogeneous pattern and positive anti-histone antibodies (<xref ref-type="fig" rid="f01">Figures 1</xref>, <xref ref-type="fig" rid="f02">2</xref> and <xref ref-type="fig" rid="f03">3</xref>).</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Psoriatic plaque on the third metacarpophalangeal joint, erythematous-violaceous
papules on the right hand dorsum</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0121-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Purpuric papules on the distal ends of the right-hand fingers</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0121-g02"/>
      </fig>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Erythematous-violaceous papule on the proximal interphalangeal joint of the left
second finger</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0121-g03"/>
      </fig>
      <p>Histopathology of an erythematous-violaceous papule on the skin of the right hand dorsum
showed a predominantly neutrophilic inflammatory infiltrate in the interstitium and in
the wall of the superficial and deep capillaries. There was fibrinoid change in the wall
of these capillaries and leukocytoclasia, consistent with leukocytoclastic vasculitis
(<xref ref-type="fig" rid="f04">Figures 4</xref> and <xref ref-type="fig" rid="f05">5</xref>).</p>
      <fig id="f04" orientation="portrait" position="float">
        <label>FIGURE 4</label>
        <caption>
          <p>Predominantly neutrophilic inflammatory infiltrate in the interstitium and in the
wall of the superficial and deep capillaries</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0121-g04"/>
      </fig>
      <fig id="f05" orientation="portrait" position="float">
        <label>FIGURE 5</label>
        <caption>
          <p>Fibrinoid alteration of the capillary walls, leukocytoclasia and red blood cell
extravasation</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0121-g05"/>
      </fig>
      <p>Based on the clinical and histopathological findings, we made the diagnosis of
drug-induced subacute cutaneous lupus erythematosus. Adalimumab was discontinued and
cyclosporine (300 mg daily) was prescribed, with no improvement. After three months with
no response, we introduced etarnecept (50 mg weekly), with gradual reduction of
cyclosporine The patient had complete resolution of the symptoms, with no recurrence of
psoriasis or lupus.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Drug-induced lupus-like syndrome (DILS) or, more specifically,TNF alpha
antagonist-induced lupus-like syndrome is a rare condition which predominantly affects
women (4:1). The average age of onset is 46-51 years. It occurs after exposure to TNF
alpha antagonist and disappears after discontinuation of such agents.<sup><xref rid="r01" ref-type="bibr">1</xref></sup></p>
      <p>The time to onset of lupus symptoms after initiation of TNF alpha inhibitors ranges from
10 days to 54 months.<sup><xref rid="r01" ref-type="bibr">1</xref></sup> Infliximab and
etanercept are the most common agents but adalimumab, more rarely, can also trigger the
disease .<sup><xref rid="r02" ref-type="bibr">2</xref>-<xref rid="r04" ref-type="bibr">4</xref></sup>Adalimumab is the first fully human recombinant monoclonal IgG1
antibody which specifically binds to tumor necrosis factor alpha and neutralizes its
biologic activity.<sup><xref rid="r04" ref-type="bibr">4</xref>-<xref rid="r07" ref-type="bibr">7</xref></sup></p>
      <p>The pathogenic mechanism for development of the TNF alpha antagonist-induced lupus-like
syndrome is not fully defined. Some authors suggest that adalimumab, similarly to
ultraviolet radiation in the pathogenesis of idiopathic lupus erythematosus, induces
apoptosis, leading to an accumulation of nucleosomal antigens of apoptotic cells. This
would cause autoantibodies to be produced by susceptible individuals. It was also
suggested that the therapeutic inhibition of TNF-alpha would increase autoimmunity by
inhibiting cytotoxic T lymphocytes.<sup><xref rid="r02" ref-type="bibr">2</xref></sup></p>
      <p>The drug-induced lupus-like syndrome can be subdivided into three clinical variants,
namley: Drug-induced systemic lupus erythematosus (SLE), drug-induced sub-acute
cutaneous lupus erythematosus and drug-induced chronic cutaneous lupus erythematosus.
Clinical and laboratory characteristics of each of the aforementioned variants are
shared by idiopathic lupus erythematosus.<sup><xref rid="r01" ref-type="bibr">1</xref></sup></p>
      <p>Systemic manifestations are: fever, weight loss, arthritis or arthralgia, myositis with
elevated muscle enzymes, serositis and haematological disorders (anemia, leucopenia and
thrombocytopenia). The most common cutaneous manifestations include maculopapular rash,
malar rash, alopecia and photosensitivity. <sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r04" ref-type="bibr">4</xref>,<xref rid="r05" ref-type="bibr">5</xref></sup> The most common presentation of vasculitis is the development of
cutaneous lesions characterized by purpura, especially in distal limb, face and ears,
and periungual telangiectasias. Histological analysis of the skin lesions usually shows
cutaneous leukocytoclastic vasculitis, a pattern found in hypersensitivity vasculitis,
involving superficial and deep dermal vessels, often with fibrin thrombi occluding
vessels and associated frank necrosis.<sup><xref rid="r05" ref-type="bibr">5</xref></sup></p>
      <p>The least rigorous criteria for diagnosis requires one or more symptoms compatible with
lupus erythematosus, ongoing exposure to a drug known to cause DILS, no prior history of
lupus erythematosus, and resolution of symptoms when the offending drug is
discontinued.<sup><xref rid="r01" ref-type="bibr">1</xref></sup> There are no
specific laboratory tests to diagnose DILS. Patients are screened for laboratory
abnormalities found in idiopathic SLE. Serological tests include: autoantibodies, blood
profile and renal function.<sup><xref rid="r01" ref-type="bibr">1</xref>-<xref rid="r03" ref-type="bibr">3</xref></sup> ANA can be positive in 80% cases and the
anti-histone antibody is considered a disease marker. However, it is less common in DILS
(17-57%).<sup><xref rid="r01" ref-type="bibr">1</xref></sup></p>
      <p>Treatment consists of drug discontinuation. Symptoms improve within 3 weeks to 6 months.
Oral or injectable steroids, hydroxychloroquine or even immunosuppressive therapy such
as azathioprine, cyclosporin, leflunomide, and methotrexate may be introduced in some
cases. <sup><xref rid="r01" ref-type="bibr">1</xref>-<xref rid="r03" ref-type="bibr">3</xref></sup><sup>.</sup><sup><xref rid="r07" ref-type="bibr">7</xref></sup></p>
      <p>The complete resolution of symptoms after discontinuation of the drug, after a careful
clinical and laboratory research, which excluded other etiologies, together with the
histological pattern found, strengthen the diagnosis of drug-induced lupus erythematosus
syndrome with leukocytoclastic vasculitis associated with the use of adalimumab. Given
the potential severity of these reactions, early diagnosis and the choice of alternative
treatment methods for a favorable disease outcome are of paramount importance.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p>Financial Support: None.</p>
      </fn>
      <fn fn-type="other">
        <p><bold>How to cite this article:</bold> Amarante CF, Acedo LMS, Rabay FMO, Campos BES,
Alvarenga Lira M L, Mandelbaum SH. Drug-induced lupus with leukocytoclastic
vasculitis: a rare expression associated with adalimumab. An Bras Dermatol. 2015;90
(3 Suppl 1):S121-4</p>
      </fn>
      <fn fn-type="other" id="fn01">
        <label>*</label>
        <p>Study conducted at the Dermatology Service of the University Hospital of Taubat&#xE9; -
University of Taubat&#xE9; (UNITAU) - Taubat&#xE9; (SP), Brazil.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Williams</surname>
              <given-names>VL</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>PR</given-names>
            </name>
          </person-group>
          <article-title>TNF alpha antagonist-induced l&#xFA;pus-like syndrome: report and review of
the literature with implications for treatment with alternative TNF alpha
antagonists</article-title>
          <source>Int J Dermatol</source>
          <year>2011</year>
          <volume>50</volume>
          <fpage>619</fpage>
          <lpage>625</lpage>
          <pub-id pub-id-type="pmid">21506984</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vezzoli</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Violetti</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Serini</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Muratori</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Berti</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Crosti</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Cutaneous lupus erythematosus induced by adalimumab</article-title>
          <source>J Dermatol</source>
          <year>2011</year>
          <volume>38</volume>
          <fpage>283</fpage>
          <lpage>284</lpage>
          <pub-id pub-id-type="pmid">21342233</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Al-Niaimi</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Adalimumab-induced lupus erythematosus</article-title>
          <source>Eur J Dermatol</source>
          <year>2009</year>
          <volume>19</volume>
          <fpage>380</fpage>
          <lpage>380</lpage>
          <pub-id pub-id-type="pmid">19451046</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fiorino</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Danese</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pariente</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Allez</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Paradoxical immune-mediated inflammation in inflammatory bowel disease
patients receiving anti-TNF-a agents</article-title>
          <source>Autoimmun Rev</source>
          <year>2014</year>
          <volume>13</volume>
          <fpage>15</fpage>
          <lpage>19</lpage>
          <pub-id pub-id-type="pmid">23777821</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Perez-Alvarez</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>P&#xE9;rez-de-Lis</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ramos-Casals</surname>
              <given-names>M</given-names>
            </name>
            <collab>BIOGEAS study group</collab>
          </person-group>
          <article-title>Biologics-induced autoimmune diseases</article-title>
          <source>Curr Opin Rheumatol</source>
          <year>2013</year>
          <volume>25</volume>
          <fpage>56</fpage>
          <lpage>64</lpage>
          <pub-id pub-id-type="pmid">23114587</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chew</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Bennett</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Barker</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kirkham</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Successful treatment of severe psoriasis and psoriatic arthritis with
adalimumab</article-title>
          <source>Br J Dermatol</source>
          <year>2004</year>
          <volume>151</volume>
          <fpage>492</fpage>
          <lpage>496</lpage>
          <pub-id pub-id-type="pmid">15327561</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Exarchou</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Voulgari</surname>
              <given-names>PV</given-names>
            </name>
            <name>
              <surname>Markatseli</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Zioga</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Drosos</surname>
              <given-names>AA</given-names>
            </name>
          </person-group>
          <article-title>Immune-mediated skin lesions in patients trated with anti-tumour
necrosis factor alpha inhibitors</article-title>
          <source>Scand J Rheumatol</source>
          <year>2009</year>
          <volume>38</volume>
          <fpage>328</fpage>
          <lpage>331</lpage>
          <pub-id pub-id-type="pmid">19579151</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mart&#xED;n</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Ricart</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Alc&#xE1;cer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rausell</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Arana</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Adalimumab-induced lupus erythematosus</article-title>
          <source>Lupus</source>
          <year>2008</year>
          <volume>17</volume>
          <fpage>676</fpage>
          <lpage>678</lpage>
          <pub-id pub-id-type="pmid">18625641</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Criado</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Criado</surname>
              <given-names>RFJ</given-names>
            </name>
          </person-group>
          <source>Rea&#xE7;&#xF5;es adversas a drogas: o espectro dermatol&#xF3;gico na pr&#xE1;tica
cl&#xED;nica</source>
          <publisher-loc>Barueri</publisher-loc>
          <publisher-name>Editora Manole LTDA</publisher-name>
          <year>2014</year>
          <fpage>430</fpage>
          <lpage>436</lpage>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
